secwatch.observer — SEC 8-K summary
======================================

Issuer:     GLAUKOS Corp (GKOS)
CIK:        0001192448
Form:       8-K
Filed at:   2024-05-01T23:59:59+00:00
Accession:  0001558370-24-006383
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Record Q1 net sales of $85.6M (+16% YoY); raised 2024 guidance to $357-$365M
----------------------------------------------------------------------------

- Glaucoma segment sales $67.2M (+20% YoY); Corneal Health $18.4M (+4% YoY).
- GAAP gross margin 76%; non-GAAP gross margin 83%.
- GAAP net loss per share ($0.82); non-GAAP net loss per share ($0.70) includes $11.7M IPR&D charge.
- Raised 2024 net sales guidance from $350-$360M to $357-$365M.
- Cash and investments ~$279M at quarter end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1192448/000155837024006383/0001558370-24-006383-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1192448/000155837024006383/gkos-20240501x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-006383

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer